PMID- 30842155
OWN - NLM
STAT- MEDLINE
DCOM- 20190311
LR  - 20190311
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 39
IP  - 3
DP  - 2019 Mar
TI  - Digital Analysis of BCL2 Expression in Laryngeal Squamous Cell Carcinoma.
PG  - 1253-1257
LID - 10.21873/anticanres.13235 [doi]
AB  - BACKGROUND: Deregulation of apoptosis is critical regarding the development and 
      progression of malignancies, including laryngeal squamous cell carcinoma (LSCC). 
      B-Cell lymphoma 2 (BCL2) (gene locus:18q21.33), located on the outer 
      mitochondrial membrane, acts mainly as an anti-apoptotic factor suppressing and 
      blocking apoptotic signal transduction. MATERIALS AND METHODS: Fifty (n=50) 
      primary LSCC tissue sections were used. Immunohistochemistry and digital image 
      analysis were implemented for evaluating BCL2 protein expression levels. RESULTS: 
      High BCL2 protein expression levels were observed in 21/50 (42%) LSCC tissue 
      sections, whereas the remaining cases (n=29) demonstrated a low expression. 
      Overall, BCL2 expression was associated with grade (p=0.046) and anatomical 
      region of the examined malignancies (transglottic, p=0.047). Interestingly, high 
      BCL2 expression levels were strongly associated with radiotherapy-based only 
      regimens (p=0.01) in corresponding patients. CONCLUSION: BCL2 overexpression was 
      found to be correlated with an aggressive phenotype (advanced grade of 
      differentiation) in LSCC, also demonstrating a potential selective anatomic 
      localization (transglotic region). Additionally, BCL2 overexpression appears to 
      be a negative regulator for successful radiotherapy implementation by reducing 
      the apoptotic process in patients.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Chrysovergis, Aristeidis
AU  - Chrysovergis A
AD  - First ENT Department, Hippocration Hospital, University of Athens, Athens, 
      Greece.
FAU - Papanikolaou, Vasileios S
AU  - Papanikolaou VS
AD  - First ENT Department, Hippocration Hospital, University of Athens, Athens, 
      Greece.
FAU - Tsiambas, Evangelos
AU  - Tsiambas E
AD  - Department of Immunohistochemistry and Molecular Biology, 401 General Army 
      Hospital, Athens, Greece tsiambasecyto@yahoo.gr.
FAU - Ragos, Vasileios
AU  - Ragos V
AD  - Department of Maxillofacial Surgery, Medical School, University of Ioannina, 
      Ioannina, Greece.
FAU - Peschos, Dimitrios
AU  - Peschos D
AD  - Department of Physiology, Medical School, University of Ioannina, Ioannina, 
      Greece.
FAU - Kyrodimos, Efthymios
AU  - Kyrodimos E
AD  - First ENT Department, Hippocration Hospital, University of Athens, Athens, 
      Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
SB  - IM
MH  - Carcinoma, Squamous Cell/*metabolism/radiotherapy
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/*metabolism/radiotherapy
MH  - Male
MH  - Proto-Oncogene Proteins c-bcl-2/*metabolism
OTO - NOTNLM
OT  - BCL2
OT  - Carcinoma
OT  - DIA
OT  - apoptosis
OT  - larynx
EDAT- 2019/03/08 06:00
MHDA- 2019/03/12 06:00
CRDT- 2019/03/08 06:00
PHST- 2019/01/09 00:00 [received]
PHST- 2019/02/15 00:00 [revised]
PHST- 2019/02/19 00:00 [accepted]
PHST- 2019/03/08 06:00 [entrez]
PHST- 2019/03/08 06:00 [pubmed]
PHST- 2019/03/12 06:00 [medline]
AID - 39/3/1253 [pii]
AID - 10.21873/anticanres.13235 [doi]
PST - ppublish
SO  - Anticancer Res. 2019 Mar;39(3):1253-1257. doi: 10.21873/anticanres.13235.